Global Veterinary Oncology Market Size study, by Therapy (Surgery, Radiotherapy, Chemotherapy, Immunotherapy, Others) by Animal type (Canine, Feline) by Cancer Type (Lymphoma, Mast Cell Cancer, Mammary and Squamous Cell Cancer, Others) and Regional Foreca

Global Veterinary Oncology Market Size study, by Therapy (Surgery, Radiotherapy, Chemotherapy, Immunotherapy, Others) by Animal type (Canine, Feline) by Cancer Type (Lymphoma, Mast Cell Cancer, Mammary and Squamous Cell Cancer, Others) and Regional Forecasts 2022-2028Global Veterinary Oncology Market is valued approximately USD 207.5 million in 2021 and is anticipated to grow with a healthy growth rate of more than 12.1% over the forecast period 2022-2028. Veterinary oncology is the treatment of cancer-stricken pets in order to improve their quality of life. One of the most common causes of mortality in pets is cancer. Skin cancer and bone cancer are more common in dogs and cats. Due to constant exposure of animal skin to UV rays, skin tumors are the most prevalent and often diagnosed cancer in domestic animals. Veterinarians utilize the HHHHHMM scale to assess the quality of life of pet owners before making treatment decisions for diseases like cancer. The rising prevalence of cancer in the pet population, together with the increased use of veterinary cancer therapy as a treatment strategy, is driving market expansion. Another element driving market expansion is the global use of canine cancer registry to quantify cancer incidences. According to Frontiers in Veterinary Science in February 2019, The Swiss Canine Cancer Registry (SCCR) was used as a data source and was developed for future comparison research of canine and human cancers.. This database is also useful in reducing the occurrence of malignant tumours in the human population, resulting in market expansion. Researchers working on veterinary oncology studies are helping to propel the veterinary oncology market forward. For example, the University of Illinois conducted a study in August 2017 that involved more precise identification of metastasis (cancer spread throughout the body) in dogs with head and neck cancers. Furthermore, market participants are concentrating on new product development and strategic partnerships. For example, in 2018, AdvaVet, an Oasmia Pharmaceutical AB company, launched XR17 technology, which is based on nanoparticle formulation and makes a single Active Pharmaceutical Ingredient (API) or numerous APIs water soluble. It is a combined therapy that is also used to treat a variety of cancer conditions in pets. Major drivers driving the market are increased expenditure on animal healthcare in developed economies due to rising willingness to spend on pet healthcare by owners and government initiatives for veterinary cancer treatment. In addition, the American Veterinary Medical Association (AVMA) predicted in October 2019 that one out of every four dogs may have neoplasia at some point in their lifetimes. However, the high cost of veterinary cancer therapy, as well as side effects of oncology medications including as hair loss, decreased appetite, and vomiting, will stifle market expansion between 2022 and 2028.

The key regions considered for the global Veterinary Oncology Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the veterinary oncology market. Over the forecast period, the segment is expected to dominate the market. The growing focus on pet health, the presence of a large number of pet medicine manufacturing companies, and the rapid acceptance of novel pet care medications are all contributing to market growth. Furthermore, the government's increased support for pet oncology treatment in this region, as well as the existence of market behemoths in the oncology market, are boosting the market. The market in Asia Pacific is likely to develop over the forecast period as veterinarians become more aware of various treatment procedures for pets, veterinary healthcare infrastructure improves, and animal healthcare expenditure rises.

Major market player included in this report are:
PetCure Oncology
Zoetis
Karyopharm Therapeutics, Inc.
Varian Medical Systems
Accuray Incorporated
Boehringer Ingelheim GmbH
Elanco
One Health
Regeneus Ltd.
Morphogenesis, Inc
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Therapy
Surgery
Radiotherapy
Chemotherapy
Immunotherapy
Others
By Animal type:
Canine
Feline
By Cancer Type:
Lymphoma
Mast Cell Cancer
Mammary and Squamous Cell Cancer
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Veterinary Oncology Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

PetCure Oncology
Zoetis
Karyopharm Therapeutics, Inc.
Varian Medical Systems
Accuray Incorporated
Boehringer Ingelheim GmbH
Elanco
One Health
Regeneus Ltd.
Morphogenesis, Inc

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.